Personalized vaccine trial aims to stop bladder Cancer's return

NCT ID NCT06305767

Summary

This study is testing whether adding a personalized cancer vaccine (V940) to standard immunotherapy (pembrolizumab) can better prevent cancer from returning in people with high-risk muscle-invasive bladder cancer after surgery. The vaccine is custom-made for each person based on proteins found on their own cancer cells, aiming to train their immune system to recognize and attack remaining cancer cells. Researchers will compare how long people stay cancer-free and monitor safety in about 230 participants.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0102)

    Orlando, Florida, 32804, United States

  • Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 1102)

    Uppsala, Uppsala County, 751 85, Sweden

  • Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 1201)

    Ankara, 06800, Turkey (Türkiye)

  • Auckland City Hospital ( Site 1901)

    Auckland, 1023, New Zealand

  • Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli-UOSC Oncologia ( Site 0503)

    Naples, Napoli, 80131, Italy

  • BC Cancer Vancouver ( Site 0004)

    Vancouver, British Columbia, V5Z 4E6, Canada

  • Bradfordhill-Clinical Area ( Site 1501)

    Recoleta, Santiago, Region M. de Santiago, 8420383, Chile

  • CIDO SpA ( Site 1509)

    Temuco, Región de la Araucanía, 4810148, Chile

  • Caritas-Krankenhaus St. Josef-Klinik fuer Urologie ( Site 0404)

    Regensburg, Bavaria, 93053, Germany

  • Centre Hospitalier de l'Université de Montréal ( Site 0005)

    Montreal, Quebec, H2X 3E4, Canada

  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0001)

    Québec, Quebec, G1J 1Z4, Canada

  • Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0002)

    Sherbrooke, Quebec, J1H 5H4, Canada

  • Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 0801)

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland

  • Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0400)

    Berlin, 10117, Germany

  • Cleveland Clinic Main ( Site 0100)

    Cleveland, Ohio, 44195, United States

  • Clinical Research Center Spółka z ograniczoną odpowiedzialnością MEDIC-R Sp.k ( Site 0805)

    Poznan, Greater Poland Voivodeship, WLK 61-731, Poland

  • Clínica Universitaria Colombia ( Site 1600)

    Bogotá, Bogota D.C., 111321, Colombia

  • Duke Cancer Institute ( Site 0107)

    Durham, North Carolina, 27710, United States

  • Ege Universitesi Hastanesi-Medical Oncology ( Site 1203)

    Izmir, 35100, Turkey (Türkiye)

  • FALP ( Site 1500)

    Santiago, Region M. de Santiago, 7500921, Chile

  • Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0502)

    Milan, Lombardy, 20133, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 0504)

    Rome, Lazio, 00168, Italy

  • Fox Chase Cancer Center ( Site 0106)

    Philadelphia, Pennsylvania, 19111, United States

  • Fundacion Valle del Lili- CIC-Oncology CIC ( Site 1608)

    Cali, Valle del Cauca Department, 760032, Colombia

  • Gartnavel General Hospital-Clinical Trials Unit ( Site 1301)

    Glasgow, Glasgow City, G12 0YN, United Kingdom

  • Gustave Roussy ( Site 0303)

    Villejuif, Île-de-France Region, 94805, France

  • HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 1003)

    Pozuelo de Alarcón, Madrid, 28223, Spain

  • HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Medical Oncology ( Site 1001)

    Seville, 41013, Spain

  • Hacettepe Universite Hastaneleri-oncology hospital ( Site 1200)

    Ankara, 06230, Turkey (Türkiye)

  • Hopital Claude Huriez - CHU de Lille ( Site 0301)

    Lille, Nord, 59037, France

  • Hospital Germans Trias i Pujol-Instituto Catalán de Oncología de Badalona ( Site 1006)

    Badalona, Barcelona, 08916, Spain

  • Hospital Militar Central Luis Arias Schereiber ( Site 1700)

    Lima, 1507, Peru

  • Hospital Universitari Vall d'Hebron-Oncology ( Site 1002)

    Barcelona, 08035, Spain

  • Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1005)

    Madrid, Madrid, Comunidad de, 28034, Spain

  • Houston Methodist Hospital-Department of Urology ( Site 0111)

    Houston, Texas, 77030, United States

  • Hôpital Saint-Louis ( Site 0304)

    Paris, 75475, France

  • IPOR Instituto Peruano de Oncología & Radioterapia ( Site 1702)

    Lima, 15036, Peru

  • Icahn School of Medicine at Mount Sinai ( Site 0101)

    New York, New York, 10029, United States

  • Institut de Cancérologie de l'Ouest ( Site 0300)

    Angers, Maine-et-Loire, 49055, France

  • Instituto Nacional De Cancerologia-Oncología Clínica ( Site 1606)

    Bogota, Cundinamarca, 111151, Colombia

  • Karolinska Universitetssjukhuset Solna ( Site 1101)

    Stockholm, Stockholm County, 171 64, Sweden

  • Koc Universitesi Hastanesi ( Site 1206)

    Istanbul, 34025, Turkey (Türkiye)

  • Korea University Anam Hospital ( Site 2002)

    Seoul, 02841, South Korea

  • Macquarie University-MQ Health Clinical Trials Unit ( Site 1803)

    Macquarie University, New South Wales, 2109, Australia

  • Mater Misericordiae Limited ( Site 1808)

    South Brisbane, Queensland, 4101, Australia

  • Memorial Ankara Hastanesi-Medical Oncology ( Site 1204)

    Ankara, 06520, Turkey (Türkiye)

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Moczowego ( Site 0800)

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • ONCOCENTRO APYS-ACEREY ( Site 1506)

    Viña del Mar, Región de Valparaíso, 2520598, Chile

  • Oddzial Onkologii Klinicznej z Pododdzialem Chemioterapii Jednodniowej ( Site 0802)

    Koszalin, West Pomeranian Voivodeship, 75-581, Poland

  • Oncopole Claudius Regaud ( Site 0302)

    Toulouse, Haute-Garonne, 31059, France

  • Oncosalud ( Site 1701)

    Lima, 15036, Peru

  • One Clinical Research ( Site 1807)

    Nedlands, Western Australia, 6009, Australia

  • Ospedale San Martino-U.O. Oncologia Medica 1 ( Site 0500)

    Genoa, Liguria, 16132, Italy

  • Ospedale San Raffaele-Oncologia Medica ( Site 0501)

    Milan, 20132, Italy

  • Pontificia Universidad Catolica de Chile ( Site 1503)

    Santiago, Region M. de Santiago, 832000, Chile

  • Princess Margaret Cancer Centre ( Site 0003)

    Toronto, Ontario, M5G 2M9, Canada

  • Royal Free Hospital ( Site 1300)

    London, England, NW3 2QG, United Kingdom

  • Samsung Medical Center-Urology ( Site 2001)

    Seoul, 06351, South Korea

  • Seoul National University Hospital-Urology ( Site 2000)

    Seoul, 03080, South Korea

  • Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 1605)

    Valledupar, Cesar Department, 200001, Colombia

  • St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 1302)

    London, London, City of, EC1A 7BE, United Kingdom

  • Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 0806)

    Kielce, Świętokrzyskie Voivodeship, SWK 25-734, Poland

  • T.C. Saglik Bakanligi Turkiye Kamu Hastaneleri Kurumu - Baki-Istanbul Bakirkoy Sadi Konuk Training ( Site 1205)

    Istanbul, 34147, Turkey (Türkiye)

  • TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1202)

    Istanbul, 34722, Turkey (Türkiye)

  • The Christie NHS Foundation Trust ( Site 1306)

    Manchester, M20 4BX, United Kingdom

  • Torbay Hospital ( Site 1303)

    Torquay, Devon, TQ2 7AA, United Kingdom

  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 0104)

    Los Angeles, California, 90095, United States

  • UT Southwestern Medical Center ( Site 0103)

    Dallas, Texas, 75390, United States

  • Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Urologie ( Site 0405)

    Dresden, Saxony, 01307, Germany

  • University of Chicago Medical Center ( Site 0109)

    Chicago, Illinois, 60637, United States

  • University of Iowa ( Site 0110)

    Iowa City, Iowa, 52242, United States

  • Universitätsklinikum Halle-Universitätsklinik und Poliklinik für Urologie ( Site 0402)

    Halle, Saxony-Anhalt, 06120, Germany

  • Westmead Hospital ( Site 1802)

    Westmead, New South Wales, 2145, Australia

  • klinikum rechts der isar der technischen universität münchen-Urologische Klinik und Poliklinik ( Site 0401)

    Munich, Bavaria, 81675, Germany

Conditions

Explore the condition pages connected to this study.